Questões de Concurso
Foram encontradas 6.683 questões
Resolva questões gratuitamente!
Junte-se a mais de 4 milhões de concurseiros!
Ano: 2023
Banca:
OBJETIVA
Órgão:
Prefeitura de Pinto Bandeira - RS
Prova:
OBJETIVA - 2023 - Prefeitura de Pinto Bandeira - RS - Professor (Letras/Inglês) |
Q2243142
Inglês
Texto associado
The intrigue behind the Bermuda Triangle
On a sunny day nearly 80 years ago, five Navy
planes took off from their base in Florida on a _________
training mission, known as Flight 19. Neither the planes nor
the crew were ever seen again. Thus was a legend born. The
Bermuda Triangle is an area roughly bounded by Miami,
Bermuda, and Puerto Rico. No one keeps statistics, but in
the last century, numerous ships and planes have simply
vanished without a trace within the imaginary triangle.
The disappearances have been attributed to the machinations of enormous sea monsters, giant squid, or extra-terrestrials. Alien abductions, the existence of a mysterious third dimension created by unknown beings, and ocean flatulence—the ocean suddenly spewing great quantities of trapped methane—have all been suggested as culprits.
The reality, say many, is far more prosaic. They argue that a sometimes treacherous Mother Nature, human error, shoddy __________________ or design, and just plain bad luck can explain the many disappearances.
"The region is highly traveled and has been a busy crossroads since the early days of European exploration," said John Reilly, a historian with the U.S. Naval Historical Foundation. "To say quite a few ships and airplanes have gone down there is like saying there are an ________ lot of car accidents on the New Jersey Turnpike—surprise, surprise."
(Fonte: National Geographic. — adaptado.)
According to the text, mark the CORRECT item:
Ano: 2003
Banca:
FCC
Órgão:
CVM
Prova:
FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242131
Inglês
Texto associado
From the IPO to the First Trade: Is Underpricing Related to the
Trading Mechanism?
Sonia Falconieri, Albert Murphy and Daniel Weaver
As documented by a vast empirical literature, IPOs are
characterized by underpricing. Most of the theoretical literature
has linked the size of underpricing to the IPO procedure used on
the primary market. In this paper, by using a matched sample of
NYSE and Nasdaq IPOs, we show that the size of underpricing
also depends on the trading method used in the IPO
aftermarket.
There are two major methods of opening trading of initial
public offerings (IPOs) in the U.S. The NYSE is an order-driven
market ....56... a call auction allows supply and demand to be
aggregated (at one location) prior to the start of trading. .....57.... ,
Nasdaq is a quote-driven market. Dealers can only specify their
best quotes, and participants have KK
58 idea of supply and
demand away from the inside quotes.
We propose a new proxy for ex ante uncertainty of firm
value and test it. Our results show that there is a larger level of
uncertainty at the beginning of trading on Nasdaq than on the
NYSE. This in turn is associated with larger levels of
underpricing for Nasdaq IPOs. We suggest that this may be due
to the different informational efficiency of the two trading
systems.
(http://www.nyse.com/marketinfo/p1020656068262.html?displayPage=%
2Fmarketinfo%2Fmarketinfo.html)
Instruções: Para responder à questão,
assinale, na folha de respostas, a letra correspondente à alternativa que preenche corretamente a lacuna do texto apresentado.
Q2241614
Inglês
Texto associado
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is
....58.... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers
from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall
victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and
acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
According to the text,
Q2241612
Inglês
Texto associado
The hard cell
Thanks to politics, stem cell research in the United States is
suffering. But not so in Sweden, which is poised to capture what
could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in
the world to enter clinical trials with a new drug that could cure
Alzheimer's disease. Four years ago this type of research was all but
stopped in the United States by political and ethical questions − which is
....58.... Sweden now seems in the best position to capture a $25 billion
market.
Any day now, the U.S. Congress is expected to pass a
sweeping new law that could dramatically inhibit researchers
from working with stem cells taken from human embryos. Such
cells, which can be used to grow a whole host of new cells and
organs, could fundamentally change the way we treat heretofore
intractable maladies like Alzheimer's disease, Parkinson's
disease, cancer, stroke, liver failure, and heart disease. The only
problem is that these cells by definition are derived from human
embryos, many of which are cloned or come from unused
fetuses collected at fertility clinics. The argument, from a certain
segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or
an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term
effect of the legislation will be to further chill all forms of scientific
inquiry and commercialization efforts in the field. Entrepreneurs
and investors are already eschewing such research − in large
part because of the additional uncertainty and risk that politics
introduce.
Of the nearly 50 private stem cell companies in the
United States, only a handful are still viable. Meanwhile, across
the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently
has 40 private stem cell companies, a number that's growing.
Sweden's leading research universities have 32 percent of the
world's stem cell inventory, close on the heels of the United
States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall
victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at
first glance seems to have it all: founding scientists include
Stanford's Dr. Weissman and Fred Gage of the Salk Institute in
La Jolla, California. An equally well-regarded expert in the
treatment of Alzheimer's, Dr. Gage spent five years in Sweden
as a researcher and now sits on a national committee on stem
cell research there. The firm's chairman is Roger Perlmutter,
Amgen's head of research.
Yet over the past two years, none of management's
efforts to help investors and even critics reconsider the stem cell
field have worked. At press time, the stock was thinly traded and
sitting in the neighborhood of 50 cents. With less than $15
million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January
2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells
can't make it, who can? Geron, the only other publicly held stem
cell firm to speak of, is in a fix, too. The company's stock price is
also moribund, at $3.85 per share. Thanks to some capital
infusions a few years ago, when money came easy, Geron still
has $40 million on hand, but by the end of next year, that too will
likely be gone. Once a media darling, Geron focuses on
diagnostic tests and drugs derived from stem cells, a strategy
that's not going well. For the nine months ended last September,
revenue fell 68 percent to $955,000 and net loss widened 18
percent to $26.7 million. The company's financials were also hit
hard after it terminated an agreement with Pharmacia and
acquired research technology from Lynx Therapeutics, which
Geron bought in a desperate attempt to be seen as something
more than just a stem cell company.
The situation is quite different, however, for Sweden's
NeuroNova, which has 30 academic partners and a staff of 20.
NeuroNova is working on ways to inject stem cells into the
human brain to trigger a process called neurogenesis (the
growth of new neural cells), which could combat diseases like
Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Segundo o texto, a NeuroNova
Ano: 2008
Banca:
NCE-UFRJ
Órgão:
CVM
Provas:
NCE-UFRJ - 2008 - CVM - Inspetor
|
NCE-UFRJ - 2008 - CVM - Analista - Arquivologia |
NCE-UFRJ - 2008 - CVM - Analista - Normas Contábeis e Auditoria |
Q2240990
Inglês
Texto associado
Obama gets first taste of Oval Office
By Andrew Ward in Washington
Published: November 10 2008 18:29 | Last updated:
November 10 2008 18:29
(1) Barack Obama stepped inside the Oval Office for the first
time on Monday during a visit to the White House for talks
with George W. Bush, outgoing president. It has long been a
tradition for the president to invite his successor to the White
House before leaving office, but this year’s meeting promised
to be more substantive than usual given the urgent economic
challenges awaiting the new administration.
(2) Dana Perino, White House press secretary, refused to be
drawn on the agenda, but it was widely assumed the financial
crisis and broader economic malaise would be a central focus.
(3) The topics One likely issue for discussion are likely to include
the terms for a proposed second economic stimulus package that
Mr Obama has urged Congress to pass before he takes office.
(4) Mr Bush has signalled his willingness to consider
another stimulus – on top of the $150bn (•118bn, £96bn) of
tax relief earlier this year – to shore up the economy.
(5) But Bush officials say the president wants the
Democratic-controlled Congress to drop its opposition to
the proposed US free trade deal with Colombia in return for
him approving further stimulus measures.
Rahm Emanuel, appointed last week as Mr Obama’s chief of
staff, indicated on Sunday that his new boss would resist
any attempt by Mr Bush to force through the Colombia deal.
(6) In another potential flashpoint between the president and
president-elect, Mr Emanuel also voiced support for
Democratic efforts to extend government support to the ailing
US car industry in spite of resistance from the White House.
(7) Despite the potential for conflict, both Mr Bush and Mr Obama
have stressed their willingness to work together in a bipartisan
fashion during the transition phase since the latter beat John
McCain, the Republican candidate, in last week’s election.
(8) Looking ahead to yesterday’s meeting, Mr Obama said:
“I’m going to go in there with a spirit of bipartisanship, and
a sense that both the president and various leaders of
Congress all recognise the severity of the situation right
now and want to get stuff done.”
(9) Mr Obama harshly attacked Mr Bush and his “failed”
policies throughout the campaign, but the president has
shown no signs of taking the criticism to heart.
(10) In his statement after the election, Mr Bush lauded Mr
Obama’s win as “a triumph of the American story, a testament
to hard work, optimism and faith in the enduring promise of
our nation”.
(11) Mr Obama has visited the White House in the past, but
on Monday marked his first time inside the oval-shaped
office that he will inherit in just over two months.
(12) The two men were expected to meet alone, allowing a candid
discussion about the demands of the job and the pressing issues
Mr Obama will face when he takes office on January 20.
(13) The meeting came as aides to Mr Obama made clear the
president-elect was planning to move swiftly to revoke a
series of Bush administration policies once in office.
(14) “There’s a lot that the president can do using his executive
authority without waiting for congressional action,” said John
Podesta, co-chair of the Obama transition team. “I think he
feels like he has a real mandate for change. We need to get off
the course that the Bush administration has set.”
In paragraph 4, “to shore up the economy” means:
Conheça nossos planos